Wave Life Sciences (NASDAQ:WVE) stock surged 5.81% on Tuesday, outperforming the broader market, fueled by the company's impressive fourth-quarter financial results.
The biopharmaceutical company reported a surprise profit of $0.17 per diluted share for the fourth quarter, surpassing analysts' expectations of a $0.19 loss per share. This marked a significant turnaround from the $0.15 loss per share in the year-ago quarter.
Additionally, Wave Life Sciences' revenue for the quarter soared to $83.7 million, up a staggering 188% year-over-year and significantly higher than the consensus estimate of $28.04 million. The strong revenue growth was likely a key driver behind the company's ability to swing to a profit during the quarter.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。